Verve Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Non-cash research and development license expense in operating activity in cash flow
Amortization of premium on marketable securities
Non-cash lease expense
Net accretion of discount on marketable securities
Stock-based compensation
Change in fair value of preferred stock tranche liabilities
Change in fair value of antidilution rights
Change in fair value of success payments liabilities

Changes in operating assets and liabilities:
Collaboration receivable
Prepaid expenses and other current assets
Accounts payable
Accrued expenses and other liabilities
Success of payment liability
Deferred revenue
Operating lease liabilities
Deferred rent liability
Net cash used in operating activities
Cash flows from investing activities:
Purchases of property and equipment
Purchases of marketable securities
Maturities of marketable securities
Net cash provided by (used in) investing activities
Cash flows from financing activities
Proceeds from issuance of Preferred Stock, net
Proceeds from initial public offering, net of underwriting discount
Shareholder loan given
Payment of initial public offering costs
Proceeds from issuance of common stock, net of issuance costs
Proceeds from the issuance of common stock in connection with collaboration agreements
Payment of equity offering costs
Proceeds from exercise of stock options
Payments received on shareholder loan
Issuance of common stock under employee stock purchase plan
Net cash provided by financing activities

Increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash—beginning of period
Cash, cash equivalents and restricted cash—end of period
Supplemental disclosure of noncash investing and finnacing activities:
Property and equipment additions included in accounts payable and accrued expenses
Financing costs included in accounts payable and accrued expenses
Settlement of tranche right liability
Conversion of convertible preferred stock to common stock upon closing of initial public offering
Settlement of derivative liability by issuing common stock
Right-of-use assets obtained in exchange for new operating lease liabilities

Comments